Here are the latest CFTR-related updates I can share right now.
The FDA has recently expanded CFTR modulator options, with new approvals and label updates for modulators that extend access to rare CFTR mutations beyond traditional Trikafta eligibility. This includes newer triple-combination modulators that may reduce dosing frequency and expand coverage for patients who previously couldn’t benefit from modulators. This is part of ongoing efforts to broaden treatment for people with CF across more mutations.[1][2]
Clinical trial activity remains strong around genetic therapies and next-generation modulators. Community updates highlight ongoing and upcoming trials, including investigations into how newer modulators perform in comparison to existing therapies, and studies addressing safety signals such as mental health monitoring and potential liver effects.[3][4]
Broader CFTR genetics research continues to document variant diversity and phenotype variability. Presentations and reviews emphasize CFTR2 data, variant interpretation, and how genetic counseling intersects with treatment options as therapies evolve, with attention to CFTR-related disorders beyond classic CF.[4][8]
Related CF news covers ongoing efforts to understand inflammation, infection management, and CF-related diabetes in the era of modulators, as researchers work to maximize long-term outcomes for people living with CF.[5]
For a broader perspective, recent professional updates summarize how modulators like Trikafta and newer therapies are being integrated into care, including monitoring for side effects and expanding eligibility through regulatory approvals.[2][3]
If you’d like, I can pull more precise details on the latest approved modulators, their age or mutation criteria, and the specific safety monitoring recommendations. I can also summarize the most recent trial results or create a quick briefing tailored to your interests (e.g., adult CF patients in Los Angeles area, caregiver considerations, or coverage/affordability questions).
A new CFTR modulator treatment called Alyftrek has been approved for people with CF ages 6 and older who have CFTR mutations that are eligible for Trikafta, as well as 31 other rare mutations that have not been approved previously for any other CFTR modulator.
www.cff.orgA Potential Breakthrough Treatment for Cystic Fibrosis Enters Clinical Trial Led by CI MED and U of Iowa Researchers
medicine.illinois.eduThere's been advancement on cystic fibrosis, but there are still those living with the disease who get no relief from current treatments. Gene editing may help.
www.nhlbi.nih.govProtein clustering mechanism on the cell membrane presents a new therapeutic target for cystic fibrosis.
www.sickkids.caA new study confirms ivacaftor's impact on inflammation in people with cystic fibrosis (CF). Ivacaftor targets the defective protein that causes CF.
news.cuanschutz.edu"It's not a cure, but it's the closest thing we have," a doctor said of a new cystic fibrosis treatment.
abcnews.go.comThe latest news from the Cystic Fibrosis Foundation.
www.cff.org